Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...
Semaglutide reduces risk of cardiovascular events in patients with type 2 diabetes, finds study
Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...
Real Housewife shares warning to weight-loss drug users after terrible side effect: ‘I did everything wrong’
Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...
Fierce Pharma3d
Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
Applied Clinical Trials Online3d
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Meghan Trainor finally admits to using weight-loss drug after 'smoke show' makeover
Meghan Trainor has finally admitted to using a trendy semaglutide injectable to help her shed a substantial amount of weight ...
PharmExec5d
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Pharmabiz5d
Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC’s annual scientific session
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
Barchart on MSN5d
These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip
In the realm of investing, finding value in mega-cap stocks can often seem like searching for a needle in a haystack. Nvidia ...
News-Medical.Net on MSN5d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® ...